Seattle biotech founded by former Seagen leaders nabs $112M for three clinical-stage ADCs
ProfoundBio will use a larger-than-planned Series B to finance three clinical-stage antibody-drug conjugates, including taking its lead compound into a pivotal study and helping advance multiple Phase I-stage drugs.
The Seattle biotech’s $112 million round, disclosed Tuesday morning, will back what has become one of the hottest areas in oncology on the promise of delivering targeted, powerful and potentially safer cancer-killing drugs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.